TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 470745

Group type: EXPERIMENTAL
Intervention: Kylie sheet
Number of subjects: 19

Group type: COMPARATOR
Intervention: Cotton drawsheets
Number of subjects: 19
Study: 31056885

Group type: EXPERIMENTAL
Intervention: Intensive moxibustion plus acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Simple acupuncture
Number of subjects: 60
Study: 28121183

Group type: EXPERIMENTAL
Intervention: BRC (betalain-rich concentrate)
Number of subjects: 22
Study: 24823464

Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg daily; n = 16)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg daily; n = 16)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Tamsulosin (0.4 mg daily; n = 14)
Number of subjects: 46
Study: 23093401

Group type: EXPERIMENTAL
Intervention: Active drink (pomegranate extract) consumed during high-fat meal (ET-DUR)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Active drink (pomegranate extract) consumed 15 min before high-fat meal (ET-PRE)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (placebo drink with no pomegranate extract) consumed during high-fat meal (CONTROL)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: ET-PRE and ET-DUR
Number of subjects: 19
Study: 20145447

Group type: EXPERIMENTAL
Intervention: Reiki intervention
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 21
Study: 18634163

Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg once daily for up to 36 weeks
Number of subjects: 1207
Study: 15857162

Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD) with n-3 Polyunsaturated Fatty Acids (PUFA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Very Low Calorie Diet (VLCD) with placebo
Number of subjects: 20
Study: 12816624

Group type: EXPERIMENTAL
Intervention: Stress-reduction intervention (16-hour program)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Waiting control group (no intervention)
Number of subjects: 38
Study: 11108570

Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alpha-blocker treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Finasteride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neoadjuvant and adjuvant alpha-blocker therapy
Number of subjects: 0
Study: 7542928

Group type: EXPERIMENTAL
Intervention: Educational brochures about melanoma (2 brochures)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Control group 1 (no educational material)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Control group 2 (questionnaire and chart, no educational material)
Number of subjects: 314
Study: 2291755

Group type: EXPERIMENTAL
Intervention: Pivmecillinam 200 mg t.i.d. for 3 days
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Pivmecillinam 200 mg t.i.d. for 7 days
Number of subjects: 299
Study: 7304902

Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 41

Group type: COMPARATOR
Intervention: Diazepam 15 mg
Number of subjects: 41
Study: 31154681

Group type: EXPERIMENTAL
Intervention: No rehydration (NR)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Post-immersion rehydration (RH) with 1 L of water
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 9
Study: 28391147

Group type: EXPERIMENTAL
Intervention: Pelvic floor training programme (daily perineal massage and pelvic floor exercises from 32 weeks of pregnancy until birth)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Pelvic floor training programme
Number of subjects: 466

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 466
Study: 26371518

Group type: EXPERIMENTAL
Intervention: Atorvastatin + hydroxychloroquine 200 mg
Number of subjects: 328

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 328
Study: 23577913

Group type: EXPERIMENTAL
Intervention: Web-based training on cognitive behavioral therapy (CBT) skills
Number of subjects: 127

Group type: COMPARATOR
Intervention: Written CBT manual (Control)
Number of subjects: 127
Study: 21443446

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (n=5)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no treatment, n=5)
Number of subjects: 10
Study: 19650515

Group type: EXPERIMENTAL
Intervention: Pilot randomized controlled trial (RCT) intervention
Number of subjects: 0
Study: 17194950

Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Guided imagery
Number of subjects: 170

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 170
Study: 15081180

Group type: EXPERIMENTAL
Intervention: Staged training
Number of subjects: 495

Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 495
Study: 11495672

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (two 60‐mg tablets of BioGinkgo daily for 5 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9754980

Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg twice daily for 7 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8141105

Group type: EXPERIMENTAL
Intervention: ondansetron 1 mg three times per day for 3 days
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg three times per day for 3 days
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg three times per day for 3 days
Number of subjects: 324

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: ondansetron (all doses)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: ondansetron 1 mg
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg
Number of subjects: 324
Study: 3257872

Group type: EXPERIMENTAL
Intervention: D‐penicillamine
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Number of subjects: 162

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 162
Study: 29618331

Group type: EXPERIMENTAL
Intervention: Alerta Alcohol intervention (EC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control condition (CC)
Number of subjects: 16
Study: 27027891

Group type: EXPERIMENTAL
Intervention: Treadmill training (12 sessions of 45 minutes each, one session a day, three days a week for four weeks)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no physical training, regular social interactions following a specific lifestyle program)
Number of subjects: 17
Study: 23810271

Group type: EXPERIMENTAL
Intervention: 3% lidocaine emulsion formulation (NOPAYNE™)
Number of subjects: 29

Group type: COMPARATOR
Intervention: 4% aqueous solution (Xylocaine™)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 29
Study: 23774308

Group type: EXPERIMENTAL
Intervention: Submucosal administration of 300 U onabotulinumtoxinA (onaBoNT/A)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Detrusor administration of 300 U onabotulinumtoxinA (onaBoNT/A)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Comparison of submucosal vs detrusor administration
Number of subjects: 23
Study: 21968660

Group type: EXPERIMENTAL
Intervention: Skin Health Experimental Product (SHEP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19242624

Group type: EXPERIMENTAL
Intervention: McKenzie method
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Orthopaedic manual therapy
Number of subjects: 134

Group type: COMPARATOR
Intervention: Advice-only
Number of subjects: 134
Study: 16983840

Group type: EXPERIMENTAL
Intervention: i.v. dexamethasone 0.5 mg/kg
Number of subjects: 230

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 230
Study: 14523485

Group type: EXPERIMENTAL
Intervention: Vitamin C and E (600 mg/day each)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 10935153

Group type: EXPERIMENTAL
Intervention: Nutrient bar (2 bars/day)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo bar
Number of subjects: 43
Study: 9411419

Group type: EXPERIMENTAL
Intervention: Thyroid carcinoma patients
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Non-toxic nodular goitre patients
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Patients with autoantibodies (ATG and/or MAB)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (30 healthy women)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Patients with anti thyroglobulin antibodies (ATG)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Patients with anti thyroid microsomal antibodies (MAB)
Number of subjects: 71
Study: 1283698

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 0
Study: 3887977

Group type: EXPERIMENTAL
Intervention: 50 mg ranitidine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 100 mg ranitidine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 300 mg cimetidine
Number of subjects: 120
Study: 30793466

Group type: EXPERIMENTAL
Intervention: Benazepril 20 mg/d
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Combination therapy (halved doses of valsartan and benazepril)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Valsartan 320 mg/d
Number of subjects: 103
Study: 29587710

Group type: EXPERIMENTAL
Intervention: Cash transfer programme
Number of subjects: 2907
Study: 26853239

Group type: EXPERIMENTAL
Intervention: BCAA (20-g divided into two doses before and after strength training)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 24970519

Group type: EXPERIMENTAL
Intervention: Video modelling
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control video (oral hygiene instruction)
Number of subjects: 180
Study: 22357964

Group type: EXPERIMENTAL
Intervention: Sodium salicylate for 4 weeks in DIO C57Bl/6 mice
Number of subjects: 16

Group type: COMPARATOR
Intervention: Salsalate for 2 weeks in a randomized double-blind placebo-controlled crossover study in men
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: In vitro salicylate treatment
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: DIO 11β‐HSD1‐deficient mice
Number of subjects: 16
Study: 20378005

Group type: EXPERIMENTAL
Intervention: NiOH treatment (0.3ng to 1.5 microg/week for 4 months, followed by 1.5 microg/week for 12 months)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: NiOH treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (low-Ni diet alone)
Number of subjects: 36
Study: 17336970

Group type: EXPERIMENTAL
Intervention: Vitamin B preparation
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both vitamin B preparation and metformin
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (standard infertility treatment only)
Number of subjects: 102
Study: 15632253

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12486516

Group type: EXPERIMENTAL
Intervention: Indomethacin 0.1%
Number of subjects: 89

Group type: COMPARATOR
Intervention: Fluorometholone 0.1%
Number of subjects: 89
Study: 10488254

Group type: EXPERIMENTAL
Intervention: Bier block solution with 2 mg of morphine sulfate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard Bier block solution without morphine sulfate
Number of subjects: 30
Study: 7659265

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg die
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg die
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg die
Number of subjects: 45
Study: 2504119

Group type: EXPERIMENTAL
Intervention: Flecainide (0.15 mg/kg/h after a loading dose of 2 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 30
Study: 30100278

Group type: EXPERIMENTAL
Intervention: Crunch exercise with Ki-hap group (CKG)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Crunch exercise with Ki-hap and verbal encouragement group (CKVG)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Crunch only exercise group (CG)
Number of subjects: 90
Study: 28077412

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) plus best medical treatment (BMT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Best medical treatment (BMT) alone
Number of subjects: 100
Study: 25604371

Group type: EXPERIMENTAL
Intervention: Indomethacin suppository
Number of subjects: 130
Study: 23168014

Group type: EXPERIMENTAL
Intervention: Bosentan (125mg bid)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 21044148

Group type: EXPERIMENTAL
Intervention: Immediate pushing
Number of subjects: 77

Group type: COMPARATOR
Intervention: Delayed pushing (2 hours)
Number of subjects: 77
Study: 17466263

Group type: EXPERIMENTAL
Intervention: Induced guilt
Number of subjects: 0
Study: 17217741

Group type: EXPERIMENTAL
Intervention: Adjusted-dose warfarin (INR 2.0 to 3.0)
Number of subjects: 335
Study: 14725326

Group type: EXPERIMENTAL
Intervention: Ajoene (0.5% gel)
Number of subjects: 37

Group type: COMPARATOR
Intervention: 5-FU (1% cream)
Number of subjects: 37
Study: 10890481

Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion plus transesophageal atrial pacing (group 2, 17 patients)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Phenylephrine infusion (group 1, 19 patients)
Number of subjects: 36
Study: 8844121

Group type: EXPERIMENTAL
Intervention: Skin prick
Number of subjects: 15

Group type: COMPARATOR
Intervention: Iontophoresis (0.13 mA for 10 s)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Iontophoresis (2.0 mA for 10 s)
Number of subjects: 15
Study: 1513113

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Multiple injections
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Two injections a day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Mean HbA1 less than 10%
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Mean HbA1 greater than 10%
Number of subjects: 45
Study: 6422538

Group type: EXPERIMENTAL
Intervention: Cimetidine, 400 mg twice daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cimetidine, 200 mg four times daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oxmetidine, 400 mg twice daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oxmetidine, 200 mg four times daily
Number of subjects: 15
Study: 31444162

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg concizumab (with potential escalation to 0.20 and 0.25 mg/kg)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg concizumab
Number of subjects: 53
Study: 28125093

Group type: EXPERIMENTAL
Intervention: L-thyroxine (L-T4) supplementation at a dose of 5 μg kg-1 day-1
Number of subjects: 51

Group type: COMPARATOR
Intervention: Untreated group (no L-T4 supplementation)
Number of subjects: 51
Study: 27085466

Group type: EXPERIMENTAL
Intervention: Orthokeratology lens wear (SiHCLW group)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (NCLW)
Number of subjects: 22
Study: 24591332

Group type: EXPERIMENTAL
Intervention: Clinically adjusted drug treatment (n=10)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Renal sympathetic denervation (RDN) (n=9)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 19
Study: 21739090

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (Group B)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% (Group L)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline (Group S)
Number of subjects: 45
Study: 19410958

Group type: EXPERIMENTAL
Intervention: FL‐41‐tinted lenses
Number of subjects: 30

Group type: COMPARATOR
Intervention: Gray‐tinted lenses
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rose-tinted lenses
Number of subjects: 30
Study: 16800833

Group type: EXPERIMENTAL
Intervention: 2 Hz transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: mock TENS
Number of subjects: 70
Study: 14989285

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 10754619

Group type: EXPERIMENTAL
Intervention: Rapacuronium 1.5 mg/kg
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Rapacuronium 2.0 mg/kg
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Rapacuronium 1.0-2.0 mg/kg
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Rapacuronium (various doses)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Rapacuronium
Number of subjects: 165
Study: 8731516

Group type: EXPERIMENTAL
Intervention: Fenfluramine challenge test (60 mg)
Number of subjects: 83
Study: 1457116

Group type: EXPERIMENTAL
Intervention: Alfentanil 250 micrograms/ml
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Midazolam 0.4 mg/ml
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Propofol 10 mg/ml
Number of subjects: 90
Study: 3889027

Group type: EXPERIMENTAL
Intervention: Stepped Care (SC) therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Referred Care (RC)
Number of subjects: 100
Study: 30624175

Group type: EXPERIMENTAL
Intervention: Microbiome profiles generated by 16S rRNA gene sequence analysis and targeted nanopore sequencing
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Clinical infection observed in DFUs
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Longitudinal profiling of microbiome
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Development of complex communities in DFUs
Number of subjects: 28
Study: 29422155

Group type: EXPERIMENTAL
Intervention: Emotional intelligence education programme (six-group discussion sessions)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 47
Study: 26762334

Group type: EXPERIMENTAL
Intervention: Multi-domain cognitive training
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Single-domain cognitive training
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cognitive training (both multi-domain and single-domain)
Number of subjects: 70
Study: 24973911

Group type: EXPERIMENTAL
Intervention: Collaborative care (CC) program for treating depression following CABG surgery
Number of subjects: 189

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 189
Study: 22417870

Group type: EXPERIMENTAL
Intervention: HER2+ve tumors (IHC 3+ and/or FISH-amplified)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: HER2‐ve tumors (ER+ve and ER‐ve combined)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: ER+veHER2‐ve subgroup
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: IHC-detected ER in ABC
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Lowest levels of ER and HER2 RNA levels within the ER+veHER2‐ve subgroup
Number of subjects: 448
Study: 19008073

Group type: EXPERIMENTAL
Intervention: Graphic-numeric scale
Number of subjects: 96

Group type: COMPARATOR
Intervention: Text-anchored scale
Number of subjects: 96
Study: 17986908

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention consisting of walking, strength, flexibility, and balance training supplemented with behavioral skills training modules, with a phased schedule (3x wk(‐1) for weeks 1-8, 2x wk(‐1) for weeks 9-24, and 1x wk(‐1) for weeks 25 to end of trial)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention with > or = 150 min x wk(‐1) of moderate activity
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Center-based attendance during PA intervention
Number of subjects: 424

Group type: COMPARATOR
Intervention: Health Education Control (SA) consisting of weekly workshops transitioning to monthly
Number of subjects: 424
Study: 16617391

Group type: EXPERIMENTAL
Intervention: (123)I‐ioflupane administration (110‐185 MBq/70 kg); thyroid blocking with 120 mg potassium iodide before and after injection.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: (123)I‐ioflupane administration; whole-body scans at 15 min and 2-3 h post-injection.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Brain SPET scans performed 3-5 h after (123)I‐ioflupane administration.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Visual examination of morphology of the nigrostriatum (NS) area.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Clinical follow-up after l‐DOPA treatment for 7 months.
Number of subjects: 16
Study: 14551174

Group type: EXPERIMENTAL
Intervention: eplerenone 50 mg qd (increased to 100 mg qd if needed)
Number of subjects: 341

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 341
Study: 10958766

Group type: EXPERIMENTAL
Intervention: Orally exhaled nitric oxide (ENO)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Healthy children (control group)
Number of subjects: 74
Study: 8793612

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg plus hydrochlorothiazide 25 mg (CAP, n = 24)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Enalapril 20 mg plus hydrochlorothiazide 12.5 mg (COR, n = 23)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg plus hydrochlorothiazide 25 mg (CAP)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Enalapril 20 mg plus hydrochlorothiazide 12.5 mg (COR)
Number of subjects: 47
Study: 1451119

Group type: EXPERIMENTAL
Intervention: Gallopamil
Number of subjects: 10
Study: 6375286

Group type: EXPERIMENTAL
Intervention: Verapamil 360 mg daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31945300

Group type: COMPARATOR
Intervention: Isoniazid 5 mg/kg daily for 7 days
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Isoniazid 10 mg/kg daily for 7 days
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Isoniazid 15 mg/kg daily for 7 days
Number of subjects: 59
Study: 28923787

Group type: EXPERIMENTAL
Intervention: BuMA Supreme SES
Number of subjects: 170

Group type: COMPARATOR
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 170
Study: 27189028

Group type: EXPERIMENTAL
Intervention: Increased mean arterial pressure (70-80 mmHg) during cardiopulmonary bypass
Number of subjects: 210

Group type: COMPARATOR
Intervention: Usual practice (mean arterial pressure 40-50 mmHg) during cardiopulmonary bypass
Number of subjects: 210